Friday, 10 May 2019 09:51

Prati-Donaduzzi is among the most innovative companies in the South of Brazil

Prati-Donaduzzi (1).jpg

According to "Campeãs da Inovação da Região Sul" ranking, the company is the leader in the Chemical sector

The award ceremony of the 15th edition of the competition for Innovation Champions of the South Region took place yesterday (16) at the Technological Park of Unisinos, in São Leopoldo (RS). In the survey, Prati-Donaduzzi, the largest producer of generic drug doses in Brazil*, was classified as "leader in the Chemical sector" and ranks 9th overall.

The competition awards the 50 most innovative companies, along with leaders by size, sector champions, as well as the highlights in the following categories: Teaching & Research, State, Philanthropic, Micro and Small Companies. The survey questionnaires were processed at the IXL Center in the United States. About 400 companies had access to the test that resulted in a list of the 50 most innovative companies in the South.

According to Eder Fernando Maffissoni, Prati-Donaduzzi CEO, recognition is the result of the company's efforts and investments made in recent years.  "We are proud of the recognition, as it highlights our strategy of growth and continuous process improvement, mainly in the expansion of the product portfolio, investments destined to Research, Development & Innovation and the opening of new markets", he says.

Innovative Projects 

In search of innovation and new market opportunities, Prati-Donaduzzi invested in order to structure a manufacturing facility for Active Pharmaceutical Ingredients (API's) in Toledo, Western Paraná. The industry will be introduced in the API's market with a pioneering product in the world, the synthetic Cannabinoids.

The main advantage of this product is its high purity, excluding the presence of tetrahydrocannabinol (THC), a psychoactive substance that causes chemical dependency.

Simultaneously, Prati is in the final stages of Myalo® clinical trials, a cannabis-based drug, which is produced from purified plant extract, indicated for the control of refractory epilepsy seizures (the most critical stage of the disease, whose incidence is more common in children). The research is being produced in partnership with USP Hospital das Clínicas - Ribeirão Preto Campus.


Prati-Donaduzzi, the pharmaceutical industry specializing in the development and production of generic drugs. Based in Toledo, western Paraná, Prati-Donaduzzi produces about 11.5 billion therapeutic doses per year and has more than 4,200 employees. The company has one of the largest portfolios of generic drugs in Brazil and aims to grow its sales and production capacity by 15% in 2019.

*IQVIA MAT FEVEREIRO/2019 PMB + NRC Doses Terapêuticas 

Read 767 times Last modified on Friday, 10 May 2019 09:59